These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11123101)

  • 1. Progress in systemic sclerosis: novel therapeutic paradigms.
    Varga J
    Curr Rheumatol Rep; 2000 Dec; 2(6):481-5. PubMed ID: 11123101
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen.
    Moazedi-Fuerst FC; Kielhauser SM; Brickmann K; Hermann J; Lutfi A; Meilinger M; Brezinschek HP; Graninger WB
    Scand J Rheumatol; 2014; 43(3):257-8. PubMed ID: 24611681
    [No Abstract]   [Full Text] [Related]  

  • 3. [Do the interferons have an antifibrotic action? The internist's point of view].
    Blétry O; Somogyi A
    Rev Med Interne; 2002 Nov; 23 Suppl 4():511s-515s. PubMed ID: 12481407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive systemic sclerosis and the lung.
    Veeraraghavan S; Sharma OP
    Curr Opin Pulm Med; 1998 Sep; 4(5):305-9. PubMed ID: 10813207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [64-year-old patient with dyspnea at rest and rapidly progressing renal failure. Systemic sclerosis with interstitial lung disease and renal crisis].
    Hellmich B; Schnabel A; Gross WL
    Internist (Berl); 1998 Oct; 39(10):1062-8. PubMed ID: 9827376
    [No Abstract]   [Full Text] [Related]  

  • 6. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?
    Wells AU; Latsi P; McCune WJ
    Am J Respir Crit Care Med; 2007 Nov; 176(10):952-3. PubMed ID: 17984310
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifocal fibrosclerosis with lung, mediastinal, pancreatic and retroperitoneal involvement in a 58-year-old man.
    Romagnoli M; Poletti V
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(1):73-5. PubMed ID: 19960792
    [No Abstract]   [Full Text] [Related]  

  • 9. Relaxins: lessons and limitations.
    Seibold JR
    Curr Rheumatol Rep; 2002 Aug; 4(4):275-6. PubMed ID: 12126574
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment.
    Sahhar J; Littlejohn G; Conron M
    Intern Med J; 2004 Nov; 34(11):626-38. PubMed ID: 15546457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon-gamma on experimental scleroderma induced by bleomycin.
    Yamamoto T; Takagawa S; Kuroda M; Nishioka K
    Arch Dermatol Res; 2000 Jul; 292(7):362-5. PubMed ID: 10966061
    [No Abstract]   [Full Text] [Related]  

  • 12. D-penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma).
    Medsger TA
    Arthritis Rheum; 1987 Jul; 30(7):832-4. PubMed ID: 3304300
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis.
    Rosenbloom J; Jiménez SA
    Arthritis Rheum; 2008 Aug; 58(8):2219-24. PubMed ID: 18668575
    [No Abstract]   [Full Text] [Related]  

  • 14. Penicillamine in the treatment of systemic sclerosis.
    Clements PJ
    Curr Rheumatol Rep; 1999 Oct; 1(1):38-42. PubMed ID: 11123013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse of skin thickening after discontinuation or decrease of azathioprine therapy in a patient with diffuse cutaneous systemic sclerosis.
    Scheja A; Hesselstrand R; Wildt M; Akesson A
    Rheumatology (Oxford); 2007 Dec; 46(12):1862-3. PubMed ID: 17971385
    [No Abstract]   [Full Text] [Related]  

  • 16. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.
    Moinzadeh P; Riemekasten G; Siegert E; Fierlbeck G; Henes J; Blank N; Melchers I; Mueller-Ladner U; Frerix M; Kreuter A; Tigges C; Lahner N; Susok L; Guenther C; Zeidler G; Pfeiffer C; Worm M; Karrer S; Aberer E; Bretterklieber A; Genth E; Simon JC; Distler JH; Hein R; Schneider M; Seitz CS; Herink C; Steinbrink K; Sárdy M; Varga R; Mensing H; Mensing C; Lehmann P; Neeck G; Fiehn C; Weber M; Goebeler M; Burkhardt H; Buslau M; Ahmadi-Simab K; Himsel A; Juche A; Koetter I; Kuhn A; Sticherling M; Hellmich M; Kuhr K; Krieg T; Ehrchen J; Sunderkoetter C; Hunzelmann N;
    J Rheumatol; 2016 Jan; 43(1):66-74. PubMed ID: 26568599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic sclerosis--a challenge in rheumatology].
    Saar P; Müller-Ladner U
    Z Rheumatol; 2006 Sep; 65(5):429-38; quiz 439-40. PubMed ID: 16897099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: have they still a role?
    Luppi F; Cerri S; Richeldi L
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S74-84. PubMed ID: 16457019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis.
    Mauhin W; Rivière S; Cabane J; Tiev KP
    Scand J Rheumatol; 2014; 43(2):170-1. PubMed ID: 24588337
    [No Abstract]   [Full Text] [Related]  

  • 20. Transforming growth factor beta within fibrotic scleroderma lungs.
    Moreland LW; Goldsmith KT; Russell WJ; Young KR; Garver RI
    Am J Med; 1992 Dec; 93(6):628-36. PubMed ID: 1466358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.